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Although 155 CTNS mutations occur in patients with the lysosomal storage disorder cystinosis, no regulatory
mutations have been reported, because the promoter has not been defined. Using CAT reporter constructs of
sequences 5′ to the CTNS coding sequence, we identified the CTNS promoter as the region encompassing nucleotides
5316 to +1 with respect to the transcription start site. This region contains an Sp-1 regulatory element (GGCGGCG)
at positions 5299 to 5293, which binds authentic Sp-1, as shown by electrophoretic-mobility–shift assays. Three
patients exhibited mutations in the CTNS promoter. One patient with nephropathic cystinosis carried a 5295
GrC substitution disrupting the Sp-1 motif, whereas two patients with ocular cystinosis displayed a 5303 GrT
substitution in one case and a 5303 T insertion in the other case. Each mutation drastically reduced CAT activity
when inserted into a reporter construct. Moreover, each failed either to cause a mobility shift when exposed to
nuclear extract or to compete with the normal oligonucleotide’s mobility shift. The CTNS promoter region shares
41 nucleotides with the promoter region of an adjacent gene of unknown function, CARKL, whose start site is
501 bp from the CTNS start site. However, the patients’ CTNS promoter mutations have no effect on CARKL
promoter activity. These findings suggest that the CTNS promoter region should be examined in patients with
cystinosis who have fewer than two coding-sequence mutations.
Introduction
Cystinosis (MIM 219800), a rare autosomal recessive
storage disease, results from impaired transport of the
disulfide amino acid cystine out of cellular lysosomes
(Gahl et al. 1982). The subsequent accumulation of cys-
tine, which crystallizes in a host of cells, destroys vari-
ous tissues at different rates (Gahl et al. 2001). In classic
nephropathic cystinosis, patients experience growth re-
tardation and renal tubular Fanconi syndrome in in-
fancy, renal failure by 10 years of age, photophobia,
hypothyroidism, and a variety of other complications
that generally occur after renal transplantation (Gahl
and Kaiser-Kupfer 1987; Theodoropoulos et al. 1993;
Gahl et al. 2001). Symptomatic treatment includes re-
placement of renal losses and thyroid-hormone supple-
mentation. However, cystine-depleting therapy with oral
cysteamine (Cystagon) serves as the primary therapy,
enhancing growth, retarding renal glomerular deterio-
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ration (Gahl et al. 1987; Markello et al. 1993), and
obviating the need for thyroid-hormone replacement
(Kimonis et al. 1995). In addition, cysteamine eyedrops
dissolve the corneal crystals responsible for photophobia
(Kaiser-Kupfer et al. 1987; Gahl et al. 2000).
Although ∼95% of patients with cystinosis exhibit
the classic, infantile nephropathic type described above,
two other categories exist. Patients with intermediate
or adolescent cystinosis develop renal failure during the
2d or 3d decades of life, whereas individuals with ocular
or non-nephropathic cystinosis have only photophobia
due to corneal crystals and never develop renal disease
(Gahl et al. 2001). The variants of cystinosis can often
be differentiated on the basis of the cystine levels found
in polymorphonuclear leukocytes or cultured fibroblasts
(Gahl et al. 2001): 5–23 nmol half-cystine/mg protein
in nephropathic cystinosis, 2–5 nmol half-cystine/mg
protein in intermediate cystinosis, and 1–2 nmol half-
cystine/mg protein in ocular cystinosis (normal range,
0–0.2 nmol half cystine/mg protein).
Some correlations have been noted between the clin-
ical phenotypes of patients with cystinosis and the mu-
tations that they carry in the cystinosis gene, CTNS.
This 12-exon gene is transcribed into an mRNA of ∼2.6
kb (Town et al. 1998). The encoded protein, named
“cystinosin,” consists of 367 amino acids and appears
Figure 1 Promoter region and its activity. a, Nucleotides within the 501-bp intergene region separating the start sites of CTNS and
CARKL. The number on the left shows the distance from the CTNS start site. The Sp-1, AP-4, and CAAT-binding protein (CBP) motifs are
underlined and in boldface. The mutations in patients 1 and 2 are boxed. The 41 nucleotides in uppercase font may contribute to both expression
of CTNS and expression of CARKL. b, CAT activities of CTNS promoter constructs. Nucleotide 1 represents the transcription start site. The
constructs portrayed on the left were inserted upstream of pbCAT. The pSV40—that is, the promoterless CAT control—plasmid, which contains
both an SV40 enhancer and an SV40 promoter, served as a positive control, and pbCAT served as a negative control. CAT activity was determined
for each construct after transient transfection into HeLa cells. A vector carrying the gene for b-galactosidase was cotransfected as a control,
for transfection efficiency. The bars represent means  SD for three determinations of CAT activity. c, CAT activities of CARKL promoter
constructs. Nucleotide 1 represents the transcription start site of CARKL.
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Table 1
Primers for PCR Amplification of CTNS Promoter and CARKL Promoter
CONSTRUCT
PRIMER
Sense Antisense
CTNS
769 to 1 5′-CATGACCAAGCTTAGACTTCATTGCGGGAAGGGC-3′ 5′-CGTCTAGAGGTCCGCTGTCACCTGACC-3′
348 to 1 5′-GCATGACCAAGCTTAGGCGAGCTTCCACGCAACCT-3′ 5′-CGTCTAGAGGTCCGCTGTCACCTGACC-3′
316 to 1 5′-GACCAAGCTTCGGCTATAGGCGGAGAGGCG-3′ 5′-CGTCTAGAGGTCCGCTGTCACCTGACC-3′
254 to 1 5′-GACCAAGCTTCTAAAGGGGGCCCCGCCCCAC-3′ 5′-CGTCTAGAGGTCCGCTGTCACCTGACC-3′
109 to 1 5′-GACCAAGCTTCCAGCTGCGCTCTGTCCGTC-3′ 5′-CGTCTAGAGGTCCGCTGTCACCTGACC-3′
81 to 1 5′-GACCAAGCTTGCGGAAACTACAACTCCCAG-3′ 5′-CGTCTAGAGGTCCGCTGTCACCTGACC-3′
109 to 130 5′-GACCAAGCTTCCAGCTGCGCTCTGTCCGTC-3′ 5′-CATGACCAAGCTTGAGGCCGCGTCCGCCTCTCAC-3′
CARKL
503 to 1 5′-CATGACCAAGCTTGAGGCCGCGTCCGCCTCTCAC-3′ 5′-CGTCTAGATTATCTCCCTGACCCGCGCAGC-3′
281 to 1 5′-GCATGACCAAGCTTAAGCTCAGACCGCCCTCCATT-3′ 5′-CGTCTAGATTATCTCCCTGACCCGCGCAGC-3′
226 to 1 5′-GACCAAGCTTTTTAGGTCCCGCCTTCCGCC-3′ 5′-CGTCTAGATTATCTCCCTGACCCGCGCAGC-3′
133 to 1 5′-GACCAAGCTTAAGACGAGAAGCCTCCATGT-3′ 5′-CGTCTAGATTATCTCCCTGACCCGCGCAGC-3′
60 to 1 5′-GACCAAGCTTAGAGCGCGGACTTGTGGGGC-3′ 5′-CGTCTAGATTATCTCCCTGACCCGCGCAGC-3′
to be an integral membrane protein, most likely func-
tioning as the lysosomal cystine transporter (Gahl et al.
1982). To date, 155 mutations in the coding sequence
have been reported (Shotelersuk et al. 1998; Town et
al. 1998; Anikster et al. 1999b; Attard et al. 1999;
McGowan-Jordan et al. 1999), and the three variants
of cystinosis have proved to be allelic, each displaying
causative mutations in CTNS (Attard et al. 1999;
Thoene et al. 1999; Anikster et al. 2000). Among pa-
tients with nephropathic cystinosis, the most prevalent
mutation is a 57,257-bp deletion removing the first nine
exons of CTNS plus a large amount of upstream se-
quence (Shotelersuk et al. 1998; Town et al. 1998; An-
ikster et al. 1999a; Forestier et al. 1999), recently found
to include a new gene called “CARKL” (MIM 605060),
for “carbohydrate kinase-like” (Touchman et al. 2000).
In a series of 70 European patients (Town et al. 1998),
33% were homozygous for the 57-kb deletion, com-
pared with 44% in an American cohort (Shotelersuk et
al. 1998). In the latter group of 108 patients with ne-
phropathic cystinosis, 2 had a smaller major deletion,
11 were homozygous and 3 were heterozygous for a
753 GrA transition (W138X), 24 exhibited 1 of 21
other mutations, and several affected individuals had
no identifiable coding-sequence mutation. Recent stud-
ies have demonstrated that patients with intermediate
(Thoene et al. 1999) or non-nephropathic cystinosis
(Anikster et al. 2000) have one severe CTNS mutation
(e.g., the 57-kb deletion or the W138X mutation) and
one mild mutation (e.g., a 928 GrA transition [G197R]
or a splicing mutation).
Despite extensive mutation analysis of patients with
cystinosis, the molecular regulation of CTNS, specifi-
cally involving its promoter and nuclear-transcription
factors, has not been elucidated. This void assumes
greater import because CTNS and CARKL are sepa-
rated by only 501 bp (fig. 1a), and this GC-rich region
may contain the promoters for both genes. In addition,
some of the patients with cystinosis in whom coding-
sequence mutations are lacking may have promoter mu-
tations. In this article, we identify the promoter regions
for CTNS and CARKL, two adjacent genes that are
aligned on separate DNA strands in different directions.
We demonstrate that a region of the CTNS promoter
binds the transcription factor Sp-1 and that other por-
tions of the CTNS/CARKL promoter area have se-
quence homology to AP-4, AP-2, and NF-1 regulatory
elements. Finally, using both functional assays and mu-
tation analysis, we identify three patients with cystinosis
who have promoter mutations as the cause of their
disease.
Patients and Methods
Patients
All patients were enrolled in a protocol approved by
the National Institute of Child Health and Human De-
velopment’s institutional review board. The diagnosis of
cystinosis was made on the basis of a typical clinical
course combined with elevated leukocyte cystine levels
and the presence of corneal crystals on slit-lamp ex-
amination. A clinical-severity score was used to assess
the phenotype of each patient (Shotelersuk et al. 1998).
The severity of the renal tubular reabsorption defect was
gauged by a Fanconi syndrome index—that is, a measure
of the daily urinary excretion of 21 amino acids per
kilogram of body weight (Charnas et al. 1991). In ad-
dition, age at presentation, leukocyte cystine value, age
at renal failure, and age at development of nonrenal
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complications served as other measurable parameters.
According to this scale, a value of 1 is extremely mild
and a value of 3 is the most severe; typical patients with
nephropathic cystinosis, including those homozygous
for the 57-kb deletion in CTNS, have a value of 2.0
(Shotelersuk et al. 1998).
Promoter Constructs
Promoter sequences of different lengths were con-
structed by use of forward primers containing HindIII
restriction sites and reverse primers containing BamHI
restriction sites (table 1). Normal control genomic DNA
was used as template for amplification of the constructs
by use of PCR beads (Amersham Pharmacia Biotech).
After an initial 4-min incubation at 96C, amplification
was performed, with denaturation at 94C for 1 min,
annealing at 60C for 30 s, and extension at 72C for
1 min. A further 10-min extension at 72C was per-
formed after completion of 35 cycles. The PCR product
was purified by a GeneClean Kit (Bio101). PCRproducts
were cloned into a TA vector (TOPO TA Cloning; In-
vitrogen) and were digested with the appropriate re-
striction enzymes. DNA was ligated into a promoterless
and enhancerless CAT vector, pbCAT, by use of a T4
DNA Ligase kit (Roche). All the promoter constructs
were sequenced to confirm the orientation and the ac-
curacy of the structure. Automated sequencing was per-
formed on a Beckman CEQ 2000, by use of a CEQ Dye
Terminator Cycle Sequencing Kit, according to the man-
ufacturer’s protocol (Beckman-Coulter). For constructs
of mutated promoters, each patient’s genomic DNA
served as a template for PCR amplification using the
primer set containing nucleotides 348 to 1 (table 1,
upper section).
Mutation Analysis of CTNS in Patients with Cystinosis
Detection of the 57-kb deletion in the heterozygous
state was accomplished by use of primers flanking the
deletion. This gave a 423-bp product if the deletion was
present and gave no product if the deletion was absent
(Anikster et al. 1999a). To detect other mutations in
CTNS, genomic DNA of each patient was isolated from
whole blood and was screened by direct DNA sequenc-
ing of exons 3–12, by use of primer conditions reported
elsewhere (Shotelersuk et al. 1998; Town et al. 1998).
Automated sequencing was performed as described
above.
Transfections and Chloramphenicol Acetyltransferase
(CAT) Assays
HeLa cells were cultured in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal calf serum,
glutamine (2 mM), penicillin (100 units/ml), and strep-
tomycin (100 mg/ml). The cells were grown in six-well
plates, to ∼70%–80% confluence. Transient transfec-
tions were performed by use of 1 mg of CAT reporter
promoter construct (Promega); pSV40 b-galactosidase
plasmid (Promega) served as a control for transfection
efficiency. Lipofectamine (Life Technologies) was used
as a transfection reagent. After 48 h, the cells were rinsed
with phosphate-buffered saline (PBS) and were harvest-
ed into 200 ml of lysis buffer (Promega). CAT activity
was analyzed by incubation of cell extracts (110 ml)
with [14C]-chloramphenicol (0.225 mCi, specific activity
56.2 mCi/mmol or 2,079.4 MBq/mmol; NEN) and n-
butyryl coenzyme A (Sigma) at 37C for 20 min, fol-
lowed by xylene extraction and liquid scintillation
counting (Rackbeta 1219; Perkin Elmer Life Science).
Each experiment included three wells per construct. b-
Galactosidase activity was assayed in the cell extract (10
ml) by measurement of absorbance at 420 nm, according
to the instructions provided by Promega. One unit was
defined as the activity that hydrolyzes 1 mM o-nitro-
phenyl-b-D-galactopyranoside to o-nitrophenol and ga-
lactose per minute, at pH 7.5 and 37C. The cell extract
(25 ml) was also assayed for protein, by the standard
bicinchoninic acid method (BioRad; Hercules). CAT ac-
tivity was expressed as counts per minute (cpm), of acet-
ylated chloramphenicol, produced in 20 min, per b-ga-
lactosidase unit per milligram of protein.
Electrophoretic-Mobility–Shift Assays (EMSAs)
For EMSAs, two sets of oligonucleotide probes were
used. The first set contained nucleotides 308 to 279
(5′-AATTAGGCGGAGAGGCGGCGGAAGGCGGGA-
CCTA) of the normal, wild-type CTNS promoter and
nucleotides 308 to 279 of the CTNS promoter in
patient 1, containing a GrC conversion at nucleotide
295. The second set contained nucleotides 327 to
300 (5′-AATTTCTCGGCGGGCCCCGGCTATAGG-
CGGAGA) of the wild-type promoters and nucleotides
308 to 279 of the CTNS promoters in patients 2
and 3—that is, the sets contained either the 303 GrT
transversion or the 303 T insertion. These oligonu-
cleotides were labeled with a[32P]-dATP and the Klenow
fragment of DNA polymerase I (Amersham Pharmacia),
by standard methods, according to the manufacturer’s
recommendations. Radiolabeled probe (∼2,000 cpm)
and 1 mg of HeLa-cell nuclear extract (NE) (Santa Cruz
Biotechnology) were incubated for ∼20 min in 20 ml
reaction buffer (Bandshift Kit; Amersham Pharmacia).
Sp-1 studies were performed by use of a Sp-1 Nushift
Kit supplied by Geneka Biotechnology, according to the
manufacturer’s instructions. The reaction mixture was
electrophoresed in 0.5 # TBE buffer (45 mM Tris-bo-
rate, 1 mM EDTA) on precast nondenaturing 6% poly-
acrylamide DNA-retardation gels (Novex). The gels
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Figure 2 CTNS promoter mutations. The normal sequence is
given for nucleotides 311 to 292. Arrows indicate the mutated ba-
ses—that is, a GrC change at position295 in patient 1, a GrT change
at position 303 in patient 2, and a T insertion after position 303 in
patient 3.
were dried and exposed on Biomax MR x-ray film (Ko-
dak), for different periods of time.
Results
Characterization of the CTNS Promoter
We first generated a CTNS promoter construct con-
taining the 769 bp upstream from the transcription start
site of CTNS and transfected this construct into HeLa
cells. An SV-driven b-galactosidase reporter plasmid was
cotransfected so that, on the basis of the b-galactosidase
activity, CAT activity (in cpm/mg protein) also could be
normalized for transfection efficiency. The 769 to 1
construct gave mean  SD CAT activities of 5.5 0.2
# 104 cpm/b-galactosidase unit–mg protein. A construct
of nucleotides 769 to 360 yielded virtually no CAT
activity. Both a 348 to 1 construct and a 316 to
1 construct gave CAT activities indistinguishable from
that for the 769 to 1 construct (fig. 1b). Consecutive
truncations of the complete promoter sequence gave pro-
gressively decreased CAT activities; the activity was re-
duced to 60% when a 254 to 1 construct was used
and to 35% when a 109 to 1 construct was used.
When the construct was further deleted, to 81 to 1,
the CAT activity diminished to baseline. These data in-
dicate that the DNA region encompassing nucleotides
316 to 1 contains the basal CTNS promoter and
that DNA regions encompassing nucleotides 316 to
255, nucleotides 254 to 110, and nucleotides
109 to 82 contain cis-acting elements that positively
regulate CTNS expression (fig. 1b). Sequence analysis
predicts both the presence of Sp-1 motifs at nucleotides
299 to 293 and 237 to228 and an AP-4 binding
site at nucleotides 167 to 159 (fig. 1a). A 109 to
130 construct, extending into exon 1, gave CAT ac-
tivity comparable to that given by the 109 to 1 con-
struct (fig. 1b), indicating that this portion of the 5′ UTR
of CTNS does not contain an activating element.
Characterization of the CARKL Promoter
A complete CARKL promoter construct, extending
from 503 to 1 with respect to the CARKL transcrip-
tion start site, gave mean  SD CAT activity of ∼2.6
 0.5# 104 cpm/b-galactosidase unit–mg protein. Con-
structs of 281 to 1 bp and 226 to 1 bp gave
comparable CAT activities (fig. 1c). When a construct
was further truncated, to133 to1, CAT activity was
reduced by 40%, and a 60 to 1 construct gave vir-
tually no CAT activity. Therefore, the basalCARKL pro-
moter is located between nucleotides 226 and 1, a
region that contains activating elements at nucleotides
226 to 134 and at nucleotides 133 to 61. Se-
quence analysis indicates that the region encompassing
nucleotides 133 to 60 is predicted to bind to tran-
scription factors AP-2 and NF-1.
Promoter Mutations in Patients with Cystinosis
To determine whether some patients with cystinosis
have the disease because of mutations in the promoter
region of CTNS, we screened a total of 62 patients in
whom 93 CTNS alleles had no 57-kb deletion. Each
patient’s genomic DNA in the region encompassing nu-
cleotides 348 to 1 of the CTNS promoter was am-
plified, and the sequence compared with that of 20 con-
trol alleles. Three patients, each heterozygous for a
known coding-sequence mutation, displayed a promoter
mutation in the other allele (fig. 2). Patient 1, who had
nephropathic cystinosis, had a GrC change at position
295, involving the Sp-1 regulatory element. Patient 2,
who has ocular cystinosis, had a GrT transversion at
position 303, and patient 3, who also had ocular cys-
tinosis, had a T insertion after position 303. In each
patient, the allele with the promoter mutation was
shown to have an entirely normal coding sequence.
Functional Assessment of CTNS Promoter Mutations
Each of the patients’ three promoter mutations was
tested for its effect on promoter activity, by generation
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Figure 3 EMSAs of CTNS promoter region bearing295 GrCmutation in patient 1. a,Results of double-stranded–DNAprobe consisting
of nucleotides 308 to 279, radiolabeled with a[32P]-dATP. Lane 1, No addition. Lane 2, NE added. Lane 3, NE and 100-fold excess
nonradioactive probe added. Lane 4, NE and 30-fold-molar excess nonspecific (calf thymus) DNA added. b, Results of double-stranded–DNA
probe consisting of nucleotides 308 to 279, containing the 295 GrC mutation in patient 1, radiolabeled with a[32P]-dATP. Lane 1, No
addition. Lane 2, NE added. c, Results of Sp-1 oligonucleotide probe radiolabeled with g[32P]-ATP. Lane 1, No addition. Lane 2, NE added.
Lane 3, NE and 100-fold excess nonradioactive Sp-1 oligonucleotide added. Lane 4, NE and 100-fold excess nonradioactive probe consisting
of nucleotides 308 to 279 added. Lane 5, NE and 100-fold excess nonradioactive probe consisting of nucleotides 308 to 279, with the
295 GrC mutation in patient 1, added. d, Results of double-stranded–DNA probe consisting of nucleotides 308 to 279, radiolabeled
with a[32P]-dATP. Lane 1, No addition. Lane 2, Authentic Sp-1 peptide added. Lane 3, Sp-1 peptide and nonradioactive probe consisting of
nucleotides 308 to 279 added. Lane 4, Sp-1 peptide and 30-fold-molar excess nonspecific (calf thymus) DNA added.
of 348 to 1 CTNS-CAT constructs that contained
entirely normal sequence except for the mutation under
investigation. After being transfected into HeLa cells, the
mutant promoters in patients 1, 2, and 3 produced 19%,
5%, and 16%, respectively, of the wild-type CAT
activity.
EMSAs were performed to verify binding of nuclear
proteins to the CTNS promoter’s putative regulatory
elements and to confirm the deleterious effect that each
patient’s mutation had on factor binding. A putative
regulatory-element sequence, containing nucleotides
308 to 279 and including the Sp-1 site, was radio-
labeled to serve as a probe, and a protein-DNA complex
was formed with HeLa-cell NE (fig. 3a). The formation
of the complex was efficiently blocked by an excess of
nonradioactive target DNA but not by nonspecific DNA
(fig. 3b). When target DNA (nucleotides308 to279)
containing the 295 GrC mutation in patient 1 was
used, no protein-DNA complex was formed with HeLa-
cell NEs (fig. 3b). To demonstrate that the wild-type
DNA complex had formed by virtue of its Sp-1 sequence,
we performed two sets of experiments. First, we showed
that an authentic, radiolabeled Sp-1 regulatory-element
sequence formed a DNA-protein complex with HeLa-
cell NE (fig. 3c). The complex formation was blocked
by the addition of either 100-fold excess nonradioactive
Sp-1 oligonucleotide or the normal CTNS promoter re-
gion encompassing nucleotides 308 to 279 but not
by the same region carrying the 295 GrC mutation
in patient 1 (fig. 3c). Second, we showed that authentic
Sp-1 peptide formed a DNA-protein complex with the
normal, radiolabeled CTNS promoter region encom-
passing nucleotides 308 to 279 (fig. 3d). The com-
plex formation was blocked by 100-fold excess nonra-
dioactive normal oligonucleotide but not by nonspecific
DNA (fig. 3d).
The region encompassing nucleotides 327 to 300
and containing the mutations in patients 2 and 3, was
studied in a similar fashion. When this region was used
as a radiolabeled probe, two DNA-protein complexes
were formed with HeLa-cell NE, and complex formation
was blocked by the addition of increasing concentrations
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Figure 4 EMSAs of CTNS promoter region bearing mutations in patients 2 and 3. a, Results of double-stranded DNA probe consisting
of nucleotides 327 to 300, radiolabeled with a[32P]-dATP. Lane 1, No addition. Lane 2, NE added. Lane 3, NE and 100-fold excess
nonradioactive probe added. Lane 4, NE and 300-fold excess nonradioactive probe added. Lane 5, NE and 600-fold excess nonradioactive
probe added. Lane 6,NE and 600-fold excess nonradioactive probe consisting of nucleotides327 to300, containing the303GrTmutation
in patient 2, added. Lane 7, NE and 600-fold excess nonradioactive probe consisting of nucleotides 327 to 300, containing the 303 T
insertion in patient 3, added. Arrows indicate the locations of DNA-protein complexes that can be competed against by the normal but not by
the mutant oligonucleotides. b, Results of double-stranded DNA probe consisting of nucleotides 327 to 300, containing the 303 GrT
mutation in patient 2, radiolabeled with a[32P]-dATP. Lane 1, No addition. Lane 2, NE added. Lane 3, NE and 600-fold excess nonradioactive
mutant probe added. c, Results of double-stranded DNA probe consisting of nucleotides327 to300, containing the T insertion after position
303 in patient 3, radiolabeled with a[32P]-dATP. Lane 1, No addition. Lane 2, NE added. Lane 3, NE and 600-fold excess nonradioactive
mutant probe added.
of excess nonradioactive probe (fig. 4a). However, nei-
ther nonspecific DNA (data not shown) nor the non-
radioactive region encompassing nucleotides 327 to
300 and containing the mutations in patients 3 and 4
(fig. 4a) could compete against the formation of com-
plex. In addition, radiolabeled probe consisting of the
region encompassing nucleotides 327 to 300 and
containing either the 303 GrT mutation in patient 2
(fig. 4b) or the 303 T insertion in patient 3 (fig. 4c)
did not undergo a mobility shift when NE was added.
The bands at the origin of the gels represented nonspe-
cific binding, since they could not be competed against
by 600-fold excess nonradioactive mutant probe (fig. 4b
and c).
None of the three CTNS promoter mutations, when
incorporated into a CARKL promoter construct, had
any effect on the expression of CAT reporter activity
(data not shown).
Genotype/Phenotype Correlations
Patient 1 is a 19-year-old female of Scottish-Irish and
Puerto Rican descent who has classic nephropathic cys-
tinosis. At age 8–9 mo, her weight was below the 5th
percentile and rickets was evident. At age 4 years, prior
to surgical intervention for a tonsillectomy and adeno-
idectomy, she was found to have renal tubular Fanconi
syndrome. At age 7, an eye examination showing corneal
crystals prompted the diagnosis of cystinosis. Renal fail-
ure required peritoneal dialysis, and a cadaveric renal
transplant was performed at age 8 years. The same year,
leukocyte cystine was measured as 5.3 nmol half-cystine/
mg protein, and oral cysteamine therapy was initiated.
The renal function of the allograft gradually deterio-
rated, and, by age 19 years, the patient was again re-
ceiving peritoneal dialysis. On the basis of her early age
at disease onset and renal failure and her moderate leu-
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kocyte cystine value, the cystinosis-severity score was
calculated to be 2.7, clearly within the severe range. The
patient is heterozygous for the 57-kb deletion in CTNS
and is hemizygous for a 295 promoter mutation.
Patient 2 is an 11-year-old adopted girl of German/
Norwegian heritage. Her ocular, non-nephropathic cys-
tinosis was diagnosed after ophthalmic screening re-
vealed corneal crystals. She had no renal tubular or
glomerular disease, and her leukocyte cystine value at
age 11 years was 1.3 nmol half-cystine/mg protein. On
the basis of her lack of symptoms and her low leukocyte
cystine level, her severity score was calculated to be 1.0,
indicating only ocular involvement. She has a GrA mu-
tation at position 928 in exon 9 of CTNS, resulting in
a G197R amino acid change. No other mutation was
found in the remainder of the coding sequence. The
G197R mutation has been found in several patients with
non-nephropathic cystinosis (Anikster et al. 2000) and
is considered to be a mild mutation. The patient’s second
mutation is the GrT transversion in the promoter region
encompassing nucleotide 303.
Patient 3 also has ocular, non-nephropathic cystinosis.
She is a 22-year old woman previously reported, as “case
4,” in a study by Anikster et al. (2000). On routine
ophthalmic examination at age 20 years, she was noted
to have corneal crystals. She had no renal tubular or
glomerular disease, and her leukocyte cystine level at age
21 years was 2.3 nmol half-cystine/mg protein. On the
basis of her lack of renal symptoms and her low leu-
kocyte cystine value, her severity score was estimated to
be 1.0, consistent with ocular cystinosis. Like patient 2,
this patient also had a GrA change at position 928 in
exon 9 ofCTNS, resulting in a G197R substitution,with
no other mutations in the entire coding sequence. The
patient’s mother is heterozygous for G197R and lacks
the proband’s promoter mutation, a T insertion after
position 303. However, this mutation was present in
the father’s DNA, which lacked the G197R mutation.
Discussion
Lysosomal membranes contain a broad array of integral
proteins, ranging from abundant, glycosylated peptides
such as LAMP-1 and LAMP-3, which have no proved
function, to scarce, poorly glycosylated proteins, which
transport small molecules out of lysosomes. Although a
wide variety of lysosomal membrane carriers have been
described (Thoene 1992), only three—those recognizing
cystine, sialic acid, and cobalamin—are associated with
a deficiency that causes human disease. Mutations in
CTNS, with cystinosin deficiency and defective lysoso-
mal cystine transport, cause cystinosis (Gahl et al. 1982,
2001; Town et al. 1998). Mutations in SLC17A5, with
sialin deficiency, abnormal sialic-acid transport, and
free-sialic-acid accumulation, cause two allelic disorders,
Salla disease and infantile free-sialic-acid–storagedisease
(Renlund et al. 1986; Tietze et al. 1989; Aula and Gahl
2001). Impaired cobalamin transport, which is due to
an undefined gene, results in cobalamin F disease, with
homocystinuria and methylmalonic aciduria (Rosenblatt
et al. 1985). No promoter region has been identified or
characterized for any of these disease-causing genes, or
for other genes responsible for lysosomal amino acid or
sugar transport, or for the more abundant genes for
LAMP proteins.
We now define the CTNS region responsible for reg-
ulation of its expression, describing for the first time
the features of a promoter for an integral lysosomal
membrane protein. The CTNS promoter lacks a ca-
nonical TATA-like sequence but is rich in GC sequences,
including an Sp-1 motif at nucleotides 299 to 293.
The function of this SP-1 site was confirmed by EMSAs
showing binding of authentic Sp-1 protein to this region
(fig. 4d). The critical nature of this regulatory element
is indicated by the 81% reduction, in CAT reporter
activity, observed when a single nucleotide (295) is
mutated, as in our patient 1, who has cystinosis.
CTNS resides in close proximity to CARKL, a gene
of unknown function. Of the 501 bp separating the
CTNS and CARKL start sites, 41 nucleotides in the
center (316 to 276 with respect to the CTNS start
site) appear responsible for as much as 65% of the total
CTNS-expression–stimulating capacity (fig. 1b). This
region may also contribute to CARKL expression, since
nucleotides369 to276 with respect toCTNS (226
to 133 with respect to CARKL) contain an activity
element responsible for 40% of the total CARKL-ex-
pression–stimulating capacity (fig. 1c). However, in the
three patients with cystinosis, the specific, 1-bp altera-
tions in this region, which drastically reduced CTNS
promoter function, had no effect on CARKL promoter
function. This indicates that portions of the shared pro-
moter region display specificity for one gene or the other.
To our knowledge, the phenomenon of a single region
serving as a promoter for two distinct genes has been
reported only once previously—that is, in the case of a
bidirectional promoter for poly (ADP-ribose) polymer-
ase 2 and the RNase P RNA subunit (Ame et al. 2001).
In addition to the 41 shared nucleotides, the CARKL
promoter region encompassing nucleotides 133 to
60 contains predicted transcription-factor binding
sites for AP-2 (nucleotides72 to61; i.e., 5′-CCCCC-
CTGGGCG), and NF-1 (nucleotides103 to86; i.e.,
5′-GATTGGCAGGCGACTCCC).
During the past 3 years, extensive mutation analysis
has been performed on the CTNS genes in patients with
cystinosis, and 155 different mutations have been re-
ported (Shotelersuk et al. 1998; Town et al. 1998; An-
ikster et al. 1999b, 2000; Attard et al. 1999; McGowan-
Jordan et al. 1999; Thoene et al. 1999). However, for
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several patients with cystinosis, only a single allele has
been found to have a coding-sequence mutation. The
cystinosis disease state in some of these cases has been
attributed to mutations in the promoter region ofCTNS,
although no such mutations have been identified. Elu-
cidation of the CTNS promoter now makes possible mu-
tation analysis in this region. In fact, we identified three
patients with cystinosis, each of whom is compound het-
erozygous for a functional promoter mutation and a
known coding-sequence mutation.
Patient 1, with classic nephropathic cystinosis, was
known to carry the 57-kb deletion on one allele. Her
other allele contained a GrC substitution in the 295
position in relationship to the CTNS start site. On the
basis of several pieces of evidence, this mutation ap-
peared to cause promoter dysfunction: first, the mutant
construct produced only 19% of the control amount of
CAT reporter activity when transfected into HeLa cells;
second, EMSA experiments demonstrated that an oli-
gonucleotide containing the 295 mutation failed to
form a complex with NE containing transcription fac-
tors (fig. 3b); finally, an oligonucleotide bearing the
295 mutation failed to compete with the normal Sp-
1 regulatory-element oligonucleotide for binding to Sp-
1 protein (fig. 3c), indicating that the 295 mutation
disrupted an Sp-1 binding consensus sequence. We con-
clude that the 295 mutation impairs CTNS transcrip-
tion enough to constitute this patient’s second severe
mutation, accounting for the nephropathic nature of her
disease. Impaired transcription due to a 1-bp mutation
in a promoter region is unusual, and we know of only
one report of an Sp-1 regulatory-element mutation al-
tering transcription—that is, a regulatory-element mu-
tation of the LDL-receptor gene (Koivisto et al. 1994).
A northern blot showing drastically reducedCTNSmes-
sage in patient 1 would provide further confirmation
that the promoter mutation is pathological, but the pa-
tient’s RNA is not available.
Patients 2 and 3 each have ocular, non-nephropathic
cystinosis (Anikster et al. 2000), which results from a
combination of a “severe” mutation (e.g., the 57-kb
deletion or a nonsense mutation) and a “mild”mutation
(e.g., a splicing mutation or a missense mutation not
involving a transmembrane region). For both patients
2 and 3, the mild mutation was identified as a 928 GrA
substitution, already known to confer a mild cystinosis
phenotype when associated with a severe CTNS allele
(Anikster et al. 2000). Patients 2 and 3 had nomutations
in the coding sequences of their second allele, so we
examined the promoter regions of their CTNS. In pa-
tient 2, a GrT change at position 303 was found (fig.
2), and, on transfection into HeLa cells, a construct
containing this mutation yielded only 5% of the normal
CAT reporter activity. Furthermore, a normal oligon-
ucleotide containing nucleotides327 to 300 formed
a complex with NE, whereas a similar oligonucleotide,
bearing the303 GrT mutation, did not bind (fig. 4b).
The mutant oligonucleotide also could not compete
against the normal oligonucleotide sequence for binding
to NE (fig. 4a).
For patient 3, a T insertion was identified after position
303 (fig. 2), and a construct containing this mutation
resulted in only ∼16% of normal CAT reporter activity
when transfected into HeLa cells. As in the case of the
mutation in patient 2, the mutation in patient 3 did not
permit either binding to NE (fig. 4c) or competition
against the normal binding of a 327 to 300 oligonu-
cleotide (fig. 4a). Nevertheless, the formation of two
DNA-protein complexes when we used the normal re-
gion, encompassing nucleotides327 to300, as probe
indicates that this region contains at least two transcrip-
tion-factor binding sites. Furthermore, the specific mu-
tations in patients 2 and 3 are severe enough to account
for some degree of clinical disease—that is, ocular cys-
tinosis; if the promoter mutations were “mild,” there
would likely be no clinical consequences detectable.
Just as the cystine transporter has served as the pro-
totypical lysosomal membrane carrier (Gahl et al. 1982,
2001), the CTNS promoter might serve as the prototyp-
ical promoter for integral lysosomal membrane proteins;
like most TATA-less promoters that serve housekeeping
genes, it is GC rich and contains common regulatory
elements, such as Sp-1 and AP-4. Remarkably, this pro-
moter region overlaps with that of an adjacent gene. Of
greater clinical and diagnostic interest, however, is the
finding that several patients with cystinosis have the dis-
ease because of mutations in the promoter region of
CTNS. This calls for diligence in examination of the
CTNS promoter region when mutation analysis is per-
formed on patients with any type of cystinosis.
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